Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News CRT 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

L.A. McKeown

March 10, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

Todd Neale

October 28, 2024

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News ESC Heart Failure 2024

Delays to Echo and Diagnosis Spell Poor Early Outcomes in Suspected HF

Michael O'Riordan

May 13, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Conference News HFSA 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

Shelley Wood

October 13, 2023

News Conference News HFSA 2023

PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization

L.A. McKeown

October 12, 2023

News Daily News

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Michael O'Riordan

September 18, 2023

News Daily News

Takotsubo Trigger Type Matters, With Physical Shocks Linked to Worse Outcomes

Shelley Wood

July 19, 2023

News Daily News

Journal Series Explores How Eroding Abortion Access Impacts the HF Community

Todd Neale

June 15, 2023

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

Todd Neale

March 09, 2023

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Daily News

ViV TAVR Beats Redo SAVR for Short- but Not Long-term Outcomes

L.A. McKeown

July 27, 2020

Advertisement

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Delays to Echo and Diagnosis Spell Poor Early Outcomes in Suspected HF

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Takotsubo Trigger Type Matters, With Physical Shocks Linked to Worse Outcomes

Journal Series Explores How Eroding Abortion Access Impacts the HF Community

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

ViV TAVR Beats Redo SAVR for Short- but Not Long-term Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content